Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 7/20 | 0.42 |
| ▸ | KMO | O15229 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | AGXT | P21549 | 1/20 | 0.39 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.38 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.37 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10309756 | 0.84 | GRM2 (0.39) | GRM2NOTUMMGLLALOX5AGXT | |
| SCHEMBL10175527 | 0.80 | ATM (0.43) | GRM2MGLLALOX5AGXTPRMT6 | |
| SCHEMBL25617353 | 0.78 | NOTUM (0.69) | NOTUM | |
| SCHEMBL10309786 | 0.77 | AGXT (0.40) | GRM2NOTUMMGLLALOX5AGXT | |
| SCHEMBL6501087 | 0.75 | NOTUM (0.57) | NOTUMMGLLCYP2C19 | |
| SCHEMBL4507051 | 0.73 | AGXT (0.65) | KMOMGLLALOX5AGXTPRMT6 | |
| SCHEMBL28805980 | 0.73 | NOTUM (0.42) | GRM2NOTUMKMOMAP3K5CYP2C19 | |
| SCHEMBL3265073 | 0.72 | AR (0.45) | NOTUMMGLLALOX5 | |
| SCHEMBL11197056 | 0.71 | HTR1A (0.54) | NOTUMCYP2C19 | |
| SCHEMBL4704945 | 0.71 | NOTUM (0.49) | NOTUMKMOMAP3K5CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178743-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-07-12 | — | — | US | disclosed |
| US-8148371-B2 | Adenine compound and use thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20100256118-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | DAINIPPON SUMITOMO PHARMA CO.,LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-7754728-B2 | Adenine compound and use thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256118-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | ADORA1, P2RY10, HRH4 | GRM2 935/4885NOTUM 1254/4885KMO 538/4885 |
| US-20120178743-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | ADORA1, HRH4, P2RY10 | GRM2 726/4885NOTUM 1334/4885KMO 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.